

Implementing Pharmacogenetic Testing Into Clinical Laboratories

Elaine Lyon, PhD, & Gwen McMillin, PhD

University of Utah

ARUP Laboratories

Key learning objectives

- Recognize decisions in implementing pharmacogenetic testing
- Learn about strengths and limitations of CYP genotyping
- Appreciate interpretive challenges associated with pharmacogenomic results

Overview

- How to Decide
 - Tests to offer
 - Platforms
- How to interpret
 - Complex genotypes
 - Complex phenotypes
- What to tell the health care provider
 - Report contents

Decisions: Tests to offer

- Clinical validity (mainly rely on published studies)
- Clinical utility (Is it useful?)


Case presentation

- 7 yr old boy
- Treated successfully for severe ADD with **imipramine** (Tofranil), 150 mg given at night
- Complained of thirst and then collapsed suddenly at school
- Resuscitation unsuccessful
- Autopsy negative
- Toxicology...




Metabolism of imipramine

imipramine



CYP3A4

desipramine



CYP2D6

**Inactive
Metabolites**

CYP2D6

**Inactive
Metabolites**

Imipramine/desipramine toxicity

- Early S/S are mild and anticholinergic
- Serious S/S include hypotension, coma, arrhythmias, cardiorespiratory arrest
- Progression from mild to life-threatening S/S may be rapid
- Poor metabolizers (CYP2D6) are at risk for toxicity with standard doses


Case presentation (cont)

	Imipramine	Desipramine	Total	Desipramine / Imipramine Ratio
Therapeutic			150-300 ng/mL	1-2
Serum (ng/mL) (15 min after collapse)	69	942	1,011	13.7
Cardiac blood (ng/mL)	1,100	13,000	14,100	11.8
Femoral blood (ng/mL)	470	6,000	6,470	12.8
Liver (mg/g)	35,000	449,000	484,000	12.8

Utility of pharmacogenomics

- Select the best drug, at the best dose
 - narrow therapeutic index
 - narrow opportunity for efficacy
 - known population of non-responders
 - long period of time required to assess efficacy
 - drugs with well understood phenotype-genotype relationships
- Investigate adverse drug reactions (ADRs)

Consequences of variant metabolism



Pharmacogenetics “usefulness”

- Avoid drugs not likely to work
- Predict patients’ responses (or lack of) to medication and propensity to develop side effects
- Optimize drug dosage to avoid excessive or suboptimal concentration
- Identify genetic variants contributing to variability in drug response.

Cytochrome P450s (CYPs)

Genetic variants are associated with altered drug levels, but not with disease

- CYP2D6: estimated to metabolize 25% of all prescribed drugs
- CYP2C9: 5%
- CYP2C19: 15%
- CYP3A4/5: 50%



Examples of drugs metabolized by

CYP2D6

- Antiarrhythmics
- Antipsychotics
- Antidepressants
- Opiates
- Selective serotonin reuptake inhibitor (SSRI)

CYP2C9

- Anticonvulsants
- Antidepressants
- Hypoglycemics
- Anticoagulants
- Antibacterial
- Cancer Chemotherapy
- Nonsteroidal anti-inflammatory drugs


CYP2C19

- Anticonvulsants
- Antidepressants
- Anti-ulcer
- Antimalaria
- Cancer Chemotherapy
- Proton pump inhibitors

Alleles of *CYP2D6*

- More than 80 known
 - SNPs
 - INDELs
 - Complete gene deletion or duplications

- Clinical significance of most unclear



CYP2C9- CYP2C19 most common clinically relevant variants

	CYP2C9	CYP2C19
Functional	*1	*1
Decreased Function	*2 *3*4*5	*8 *9
Non Functional	*6	*2 *3 *4 *5 *6

Decisions: Platforms

- Test Complexity
 - Number of sequence variants
 - Repeats (UGT1A1)
 - Single base changes/deletions/insertions
 - Full gene deletions/duplications
 - Full gene analysis
 - Haplotypes vs. genotypes
 - Molecular haplotyping?

IVD, ASR or laboratory developed

- FDA cleared IVDs
 - Cytochrome p450 2D6
 - Cytochrome p450 2C19
 - UGT1A1
- Other tests with clinical interest
 - Cytochrome p450 2C9
 - VKORC1 for warfarin sensitivity
 - MTHFR for methotrexate sensitivity
 - TPMT for azathioprine sensitivity
 - NAT2
 - Many others

Gene patents


- Patent

- the mutation (cyp2D6 *4)
- the use of the mutation (UGT1A1, TPMT)
- the method

- License from

- Negotiating with the license holder
- Using ASRs/IVDs that manufacturer has a licensing agreement

CYPs: Analytical challenges





Lancet 1990; 336: 529-32

- Superfamily/Pseudogenes:
 - 57 genes, 33 pseudogenes
- Gene dose important
- Many SNPs are common among alleles
- Many rare variants
- Importance of haplotypes not known

Commercial CYP genotyping product examples

- Roche Light Cycler Assays
- Tm Bioscience: 3 genes, 26 variants
- Roche AmpliChip: 2 genes, 29 variants
- GE CodeLink: 9 genes, 113 variants
- Third Wave Invader: 1 gene
- Gentris: 2 genes
- AutoGenomics
- Biotage
- Genelex
- Genaissance
- Nanogen
- Nanosphere Verigene



AmpliChip

- Solid support microarray
- FDA approved for 2D6, 2C9
- 2 genes
 - 2D6, 27
 - 2C19, 2 alleles
- Deletion
- Duplication
 - Allele with duplication



AmpliChip CYP450 REPORT

```

----- SAMPLE INFORMATION -----
Experiment Name      zoe4
Sample Name         zoe4
Sample Type         zoe4
Project             zoe4
Sample User         administrator
    
```

```

----- RESULT -----
CYP450 Gene         CYP2D6
Genotype            CYP2D6*1/CYP2D6*1
Predicted Phenotype Intermidiate Metabolizer
    
```



Site	Call	1	2A	2B	2D	3	4A	4B	4D	4J	4K	6A	6B	6C	7	8	9	10A	10B	11	15	17	19	20	29	35	36	40	41
-1584C>G	WT																												
315>A	WT																												
108C>T	HET																												
1381neT	WT																												
8835>C	WT																												
1023C>T	WT																												
1039C>T	WT																												
16590>A	WT																												
16610>C	HUT																												
1707T>del	WT																												
17580>T	WT																												
17280>A	WT																												
18460>A	HET																												
19760>A	WT																												
*20 cluster	WT																												
2539-2542deIAACT	WT																												
2549A>del	WT																												
2613-2615deIAGA	WT																												
2850C>T	HET																												
2935A>C	WT																												
31830>A	WT																												
3198C>G	WT																												
3277T>C	WT																												
40450>A	WT																												
*36C	WT																												
41800>C	HUT																												
1863 Repeat Ins	Negative																												
Gene Deletion (*5)	Negative																												
Gene Duplication	Negative																												

```

CYP450 Gene         CYP2C19
Genotype            CYP2C19*1/CYP2C19*2
Predicted Phenotype Extensive Metabolizer
    
```

Luminex Tag-It

- Three genes
 - 26 variants
- 2D6
 - 12 alleles
 - Deletion
 - Duplication (determine allele?)
- 2C9
 - 5 alleles
- 2C19
 - 7 alleles



Analytical validation

- Limited validation for FDA approved tests
- Validation for laboratory developed tests
 - Accuracy - compare to independent analysis laboratory and/or method
 - Reproducibility – within run/between run
 - Compare to published allele frequencies

Frequency of variant CYPs

Gene	Allele	Enzyme activity	Caucasians		Asians		SouthEast Asian	African American		Middle East	
CYP2C9	*2	deficient	8-13%	17%			0.50%	1-4%			5%
	*3	deficient	6-10%	7%	1.7-5%	7.5%	10%	0.5-1.5%	5%		5%
CYP2C19	*2	deficient	13%	16%	32%	32.5%	20%	17%	15%		20%
	*3	deficient			6-10%	10%	5%				
CYP2D6	*3	deficient	2%	0.5%				2%			
	*4	deficient	12-21%	19.5%				1-9%	5%	3.5%	20%
	*5	deficient	4-6%	2%	5-13%	5%	10%	4-6%	5%	1%	0%
	*10	decreased	3%	1.5%	35-50%	48%	50%	6-10%	5%	3%	15%
	*17	decreased						34%	35%	3%	5%
	Dup	increased	1-4%	1.5%	1-2%	1.6%		0.13	5%		5%

Interpretation: CYP phenotypes

Poor Metabolizer (PM): gene absent or nonfunctional

Intermediate Metabolizer (IM)



Extensive (normal) Metabolizer (EM)

Ultra-rapid Metabolizer (UM):
multiple copies of functional genes

Predicting phenotypes from genotypes


Alleles	Predicted phenotype
F/F	EM
F/DF	EM
F/NF	EM
DF/DF	IM
DF/NF	PM
NF/NF	PM
DUP-F	UM

Example:

Antidepressants and CYPs

<i>Brand Name</i>	<i>Generic Name</i>	<i>Mechanism</i>	<i>CYP Metabolism</i>
Effexor	Venlafaxine	<i>mixed</i>	CYP3A4, CYP2D6, CYP2C9, CYP2C19
Wellbutrin	Bupropion HCL	<i>mixed</i>	CYP2B6, CYP2D6, CYP1A2, CYP3A4 +
Desyrel	Trazodone	<i>mixed</i>	CYP3A4, CYP2D6
Zoloft	Sertraline	<i>SSRI</i>	CYP3A4, CYP2D6, CYP2C9, CYP2C19
Prozac	Fluoxetine	<i>SSRI</i>	CYP2B6, CYP2C9, CYP2C19, CYP3A4+
Celexa	Citalopram	<i>SSRI</i>	CYP3A4, CYP2C19, CYP2D6
Lexapro	Escitalopram	<i>SSRI</i>	CYP3A4, CYP2C19
Elavil	Amitriptyline	<i>TCA</i>	CYP3A4, CYP2D6, CYP2C19, CYP2B6+
Norpramin	Desipramine	<i>TCA</i>	CYP2D6, CYP1A2
Sinequan	Doxepine	<i>TCA</i>	CYP2D6, CYP1A2, CYP3A4
Pamelor	Nortriptyline	<i>TCA</i>	CYP1A2, CYP2D6, CYP2C19, CYP3A4
Anafranil	Clomipramine	<i>TCA</i>	CYP2D6, CYP1A2, CYP2C19, CYP3A4

Example 1: Amitriptyline




Genotype-based dosing

for drugs that are *inactivated* by the affected enzyme

	Usual Dose		UM	↑	EM	IM	↓	PM
Amitriptyline	150 mg	CYP2D6	230%		120%	90%		50%
Nortriptyline		CYP2C19	N/A		110%	80%		60%
Others		CYP2D6	230-300%		110-140%	70-100%		20-90%
		CYP2C19	N/A		100-110%	70-90%		40-70%

Example 2: Venlafaxine



CYP effects on venlafaxine (V)


■ CYP2D6

- Converts V to active metabolite (ODV)
- PM to have longer V $t_{1/2}$ and less active drug
- UM have shorter V $t_{1/2}$ and more active drug
- PM requires higher doses than EM
- UM requires lower doses


■ CYP2C9 or CYP2C19

- Prevent V inactivation
- PMs accumulate V and ODV
- More active drug and higher ratio of ODV/V (complex phenotype)
- PM may require lower doses than EM

Venlafaxine phenotypes: Parent/metabolite ratio



Co-occurrence of mutations in 2D6, 2C9, 2C19



Interpretation complexity

- Non-genetic factors
 - Diet, multiple drugs, nutraceuticals
- Multiple genes (superfamily)
- Multiple pathways
- Alleles called based on presumed haplotypes
 - *4A (1846G>A; 100C>T)
 - *4K (1846G>A; 100C>T;2850C>T)
 - 2850C>T present in many alleles

Reporting:

Information to the clinician

- Report alleles
 - (i.e. *3,*4)
- Include nucleotides
 - (i.e. 2549A>del,1846G>A/100C>T)
- Predicted phenotype
 - PM, IM, EM, UM
- Duplication
 - Functional alleles
 - Non-functional alleles
- Combined reports (2D6,2C9, 2C19)?

Reports

- Dosing adjustments not included in the report
 - Depends on medication or combination of medicines
- Recommend counseling with a clinical pharmacist

No pharmacogenomic test will replace the need to



- Monitor the patient clinically for response
- Monitor drug and/or metabolite levels, other biomarkers



Likely future directions



- Other genes
- More FDA-approved kits
- Application-based panels
- Additional “molecular autopsies”
- Changes to drug labeling
- More genotype-to-phenotype discovery of targets

Many thanks

Roberta Melis, Ph.D.

– Research scientist

■ Cindy Meadows, B.S., CLSp(MB)

– Clinical supervisor

■ Jamie Williams, B.S., CLSp(MB)

– Clinical technical specialist